Want to see HK:0314 full AI Analyst Report?
Sipai Health Technology Co., Ltd. (0314) AI Stock Analysis
Sipai Health Technology Co., Ltd.
(HKEX:0314)
The score is held back primarily by weak financial performance—continued losses and a steep 2025 revenue contraction—despite some improving signals (better gross margin, lower leverage, and modestly positive operating cash flow in 2025). Technicals provide partial support with improving short-to-medium term momentum, but valuation remains challenged due to negative earnings and no dividend yield provided.
Sipai Health Technology Co., Ltd. (0314) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 964.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 783.94K
- Price to Earnings (P/E)
- -5.6
- Beta (1Y)
- 0.33
- Revenue Growth
- -52.19%
- EPS Growth
- 97.51%
- Country
- Hong Kong
- Employees
- 3,131
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Sipai Health Technology Co., Ltd. Business Overview & Revenue Model
Company Description
Sipai Health Technology Co., Ltd. is a Chinese enterprise specializing in medical technology and health management. Its business operations are diversified across three primary divisions: Specialty Pharmacy, Physician Research Assistance, and Health...
Sipai Health Technology Co., Ltd. Financial Statement Overview
Summary
Overall financials remain pressured by ongoing operating and net losses and a sharp ~41% revenue decline in 2025. Positives include improved gross margin, meaningfully smaller losses versus 2021–2022, manageable leverage in 2024–2025, and a modest turn to positive operating cash flow in 2025—though free cash flow is still only around breakeven and past cash flow was weak.
Income Statement
28NegativeBalance Sheet
62PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.43B | 2.02B | 4.57B | 4.71B | 4.12B | 3.47B |
| Gross Profit | 332.69M | 277.08M | 386.43M | 414.70M | 337.35M | 281.06M |
| EBITDA | -201.89M | -74.82M | -225.58M | -189.21M | -565.92M | -665.44M |
| Net Income | -317.52M | -121.05M | -323.74M | -255.77M | -1.37B | -3.74B |
Balance Sheet | ||||||
| Total Assets | 1.83B | 1.60B | 2.27B | 2.82B | 2.93B | 2.89B |
| Cash, Cash Equivalents and Short-Term Investments | 597.85M | 665.35M | 919.77M | 1.13B | 1.53B | 1.61B |
| Total Debt | 24.70M | 22.59M | 66.49M | 67.56M | 67.76M | 7.52B |
| Total Liabilities | 876.01M | 703.20M | 1.06B | 1.18B | 1.10B | 8.32B |
| Stockholders Equity | 995.88M | 936.71M | 1.23B | 1.62B | 1.84B | -5.43B |
Cash Flow | ||||||
| Free Cash Flow | -124.99M | 127.00K | -67.91M | -139.24M | -193.87M | -643.33M |
| Operating Cash Flow | -121.64M | 6.36M | -59.45M | -133.50M | -182.07M | -621.92M |
| Investing Cash Flow | 374.57M | 229.67M | -622.00K | -720.81M | 1.03B | -1.02B |
| Financing Cash Flow | -269.76M | -218.77M | -184.06M | -120.55M | 81.69M | 559.29M |
Sipai Health Technology Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0314, the sentiment is Negative. The current price of 1.33 is below the 20-day moving average (MA) of 1.39, below the 50-day MA of 1.50, and below the 200-day MA of 1.75, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 41.20 is Neutral, neither overbought nor oversold. The STOCH value of 81.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0314.
Sipai Health Technology Co., Ltd. Peers Comparison
Overall Rating
HK:215956Neutral
HK:988656Neutral
HK:225152Neutral
HK:968651Neutral- HK:031450Neutral
HK:213842Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2159 | 56Neutral | HKD 528.27M | 9.61 | 28.00% | ― | 91.32% | ― |
| HK:9886 | 56Neutral | HKD 1.10B | -15.49 | -3.87% | ― | 8.73% | 80.38% |
| HK:2251 | 52Neutral | HKD 904.97M | -11.11 | -5.98% | ― | 10.67% | 57.27% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9686 | 51Neutral | HKD 820.84M | -45.36 | -5.98% | ― | -3.77% | 73.89% |
| HK:0314 | 50Neutral | HKD 745.66M | -5.63 | -11.19% | ― | -52.19% | 97.51% |
| HK:2138 | 42Neutral | HKD 645.94M | -1.61 | -25.36% | ― | -8.94% | -140.82% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0314 | Sipai Health Technology Co., Ltd. | 1.33 | -1.16 | -46.59% | |
| HK:9886 | Dingdang Health Technology Group Ltd. | 0.90 | -0.19 | -17.43% | |
| HK:2138 | EC Healthcare | 0.55 | -0.10 | -16.15% | |
| HK:2159 | Mediwelcome Healthcare Management & Technology Inc. | 1.57 | 0.40 | 34.19% | |
| HK:2251 | Beijing Airdoc Technology Co. Ltd. Class H | 9.18 | -3.79 | -29.22% | |
| HK:9686 | NEUSOFT XIKANG HOLDINGS INC. | 0.97 | 0.03 | 2.63% |
Sipai Health Technology Co., Ltd. Corporate Events
Sipai Health Tech Plans Major Disposal of Subsidiary Stake to Dashenlin
Sipai Health Technology has agreed through its wholly owned unit Sipai Investment to sell 100% of the equity in a wholly owned subsidiary, referred to as the Target Company, to Dashenlin for an aggregate consideration of RMB15 million, subject to an...
Sipai Health Technology Completes Acquisition of Jianyi Information Technology
Sipai Health Technology Co., Ltd. has completed the acquisition of 100% equity interest in Jianyi Information Technology (Shanghai) Co., Ltd. through its wholly owned subsidiary Bixun Pharmaceutical. The transaction, finalized on September 9, 2026, c...
Sipai Health Redeems RMB50 Million Wealth Product to Fund Acquisition
Sipai Health Technology’s subsidiary, Sipai Healthcare Investment, has redeemed a principal‑guaranteed cash management wealth management product from Industrial Bank, withdrawing RMB50 million on August 27, 2026, after subscribing on July...
Sipai Health Swings to Profit Despite Sharp Interim Revenue Decline
Sipai Health Technology Co., Ltd. reported a sharp drop in interim revenue for the six months ended June 30, 2026, with total revenue falling 39.6% year-on-year to RMB739.9 million. The decline was driven mainly by its specialty pharmacy business, wh...
Sipai Health Schedules Board Meeting to Approve Interim Results and Dividend
Sipai Health Technology Co., Ltd. has scheduled a board meeting for August 20, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026. The board will also consider whether to declare an interim dividend, a dec...
Sipai Health Technology Signals Profit Turnaround on Core Business Growth
Sipai Health Technology Co., Ltd., a Cayman Islands‑incorporated company listed in Hong Kong, focuses on healthcare‑related corporate insurance services and physician research assistance. Its strategy centers on expanding higher‑mar...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026